[Comment on the information by the Federal Drug and Medical Products Institute on "calcium channel blockers of the 1,4-dihydropyridine class"].
Trenkwalder
P
P
Medizinische Klinik, Krankenhaus des Landkreises Starnberg.
D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D003327:Coronary Disease / Q000139:chemically induced* / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004095:Dihydropyridines / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005858:Germany; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D013329:Structure-Activity Relationship
D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D004095:Dihydropyridines; C038806:1,4-dihydropyridine
Kommentar zur Information des Bundesinstituts für Arzneimittel und Medizinprodukte über "Calciumkanal-Blocker der 1,4-Dihydropyridin-Klasse".